Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Involvement of lysophosphatidic acid–induced astrocyte activation underlying the maintenance of partial sciatic nerve injury–induced neuropathic pain

Ueda, Hiroshi*; Neyama, Hiroyuki; Nagai, Jun; Matsushita, Yosuke; Tsukahara, Tamotsu; Tsukahara, Ryoko

doi: 10.1097/j.pain.0000000000001316
Research Paper
Buy
Editor's Choice

We have previously demonstrated that lysophosphatidic acid (LPA) plays key roles in the initial mechanisms for neuropathic pain (NeuP) development. Here, we examined whether LPA receptor mechanisms and LPA production are related to the glial activation at a late stage after partial sciatic nerve ligation (pSNL) by use of microglial inhibitor, Mac1-saporin or astrocyte inhibitor, and L-α-aminoadipate (L-AA). Although single intrathecal injection of LPA1/3 antagonist, Ki-16425 did not affect the pain threshold at day 7 after the spinal cord injury, repeated treatments of each compound gradually reversed the basal pain threshold to the control level. The intrathecal administration of a microglia inhibitor, Mac-1-saporin reversed the late hyperalgesia and LPA production at day 14 after the pSNL, whereas L-AA inhibited the hyperalgesia, but had no effect on LPA production. The involvement of LPA receptors in astrocyte activation in vivo was evidenced by the findings that Ki-16425 treatments abolished the upregulation of CXCL1 in activated astrocytes in the spinal dorsal horn of mice at day 14 after the pSNL, and that Ki-16425 reversed the LPA-induced upregulation of several chemokine gene expressions in primary cultured astrocytes. Finally, we found that significant hyperalgesia was observed with intrathecal administration of primary cultured astrocytes, which had been stimulated by LPA in a Ki-16425–reversible manner. All these findings suggest that LPA production and LPA1/3 receptor activation through differential glial mechanisms play key roles in the maintenance as well as initiation mechanisms in NeuP.

This study describes a mechanism underlying the maintenance of neuropathic pain through lysophosphatidic acid production and actions, which are mediated differentially by microglia and astrocytes.

Department of Pharmacology and Therapeutic Innovation, Nagasaki University, Graduate School of Biomedical Sciences, Nagasaki, Japan

Corresponding author. Address: Department of Pharmacology and Therapeutic Innovation, Nagasaki University Graduate School of Biomedical Sciences, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan. Tel.: +81-95-819-2421; fax: +81-05-819-2420. E-mail address: ueda@nagasaki-u.ac.jp (H. Ueda).

Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Received January 18, 2018

Received in revised form May 28, 2018

Accepted May 29, 2018

© 2018 International Association for the Study of Pain
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website